Early-phase clinical trials co-led by researchers from the Mass General Brigham Cancer Institute demonstrate the therapeutic potential of invikafusp, a novel precision immunotherapy evaluated in patients with metastatic, treatment-resistant solid tumors. The findings from the early clinical evaluation were published in Nature Medicine and simultaneously presented at the ESMO Congress 2026.
Cancer immunotherapy medications boost the body’s immune system to destroy malignant cells and have improved survival across multiple cancer types. Nevertheless, only a minority of patients experience long-term benefits because cancers frequently develop resistance to existing therapies. Furthermore, conventional immunotherapy drugs can trigger indiscriminate stimulation of T cells and broader immune mediators, resulting in severe clinical side effects.
To overcome the shortcomings of non-selective immune activation and lack of sustained potency, researchers evaluated invikafusp, also designated invikafusp alfa, a first-in-class bispecific dual T-cell agonist. The drug is engineered to bind cooperatively to two separate surface receptors on Vβ6/Vβ10 T cells: the T-cell receptor and the interleukin-2 receptor. These specific immune cells are known to infiltrate tumor tissue and mediate targeted anti-tumor responses. Upon dual binding, invikafusp drives the selective expansion of these tumor-infiltrating T cells without stimulating unrelated immune cells.
Co-lead author Ryan J. Sullivan, MD, a physician-scientist at the Mass General Brigham Cancer Institute, noted that investigators launched the development of invikafusp to extend the benefits of immunotherapy to a wider group of patients. Dr. Sullivan explained that initial laboratory experiments yielded substantial enthusiasm regarding the targeted mechanism and promise of the investigational therapy.
In the initial dose-escalating phase 1 portion of the clinical trial, investigators administered invikafusp to 34 patients with advanced solid tumors who had exhausted nearly all available therapeutic options. This dose-escalation phase demonstrated that the investigational agent was well-tolerated.
Following dose escalation, 18 patients were enrolled in a subsequent phase 2 trial to evaluate clinical activity in immune checkpoint blockade-resistant, antigen-rich tumors. Analysis of safety data across this cohort showed that treatment-related side effects were predominantly mild to moderate in severity.
Clinical efficacy assessments established that the disease control rate—defined as the proportion of patients whose tumors shrank or remained stable—reached 59.3% at optimal doses of invikafusp. Meaningful tumor shrinkage was documented in 15% of treated patients. Correlative biological analyses confirmed that invikafusp selectively and potently expanded both circulating and intratumoral Vβ6/Vβ10 T cells, with cellular expansion peaking at the optimal dosing schedules.
Dr. Sullivan emphasized that additional clinical trials remain necessary to identify precisely which patient subgroups will benefit most from treatment, though the early data support continued development. The trial was co-first authored by Ryan J. Sullivan of Mass General Brigham Cancer Institute, Nicholas P. Tschernia of the National Cancer Institute, and Claire F. Friedman of Memorial Sloan Kettering Cancer Center, with Lillian L. Siu of Princess Margaret Cancer Centre and James L. Gulley of the National Cancer Institute serving as co-senior authors.
The START-001 study received funding support from both commercial and public research institutions. Financial backing was provided in part by Marengo Therapeutics alongside the National Institutes of Health’s Intramural Research Program of the National Cancer Institute’s Center for Cancer Research under project identifier ZIA BC 010666. In addition to primary financial sponsorship, Marengo Therapeutics supported professional medical writing assistance during the preparation of the study documentation, which was provided by Kathleen M. Ohleth and Pamela Harvey of Acumen Medical Communications.
The published report also outlined several corporate affiliations and professional financial disclosures among the investigators. Multiple contributing study authors are employees of Marengo Therapeutics, the biopharmaceutical company developing invikafusp. In addition, Dr. Sullivan reported institutional research funding from an array of pharmaceutical developers, including BioNTech SE, Bristol Myers Squibb, Genentech/Roche, Georgiamune, Immunocore, Marengo Therapeutics, Merck, Moderna, Novartis, Pfizer, Relay, SpringWorks Therapeutics, and Synthekine. Dr. Sullivan has likewise served as an external consultant or advisory board member for Marengo Therapeutics, Merck, Novartis, Pfizer, PharmaMar, and Replimune, with further individual co-author disclosures documented in the journal publication.
The trial was spearheaded from within the Mass General Brigham healthcare network, an integrated academic system that operates as a nonprofit organization committed to patient care, biomedical research, medical teaching, and community service. Recognized as one of the nation’s foremost biomedical research organizations, the system encompasses several Harvard Medical School teaching hospitals alongside academic medical centers, community and specialty hospitals, physician networks, community health centers, home care, long-term care services, and a dedicated health insurance plan.
The peer-reviewed paper formally appeared on October 23, 2026, registered under digital object identifier 10.1038/s41591-026-04711-0, followed by institutional dissemination on November 11, 2026. While co-lead investigators represented Mass General Brigham, the National Cancer Institute, Memorial Sloan Kettering Cancer Center, and Princess Margaret Cancer Centre, the authors noted that a comprehensive roster of contributing researchers and full disclosure statements are detailed within the final peer-reviewed journal publication.
Subject of Research: Phase 1/2 clinical trial results of the dual T-cell agonist invikafusp in advanced solid tumors
Article Title: Novel cancer immunotherapy drug generates promising clinical trial results
Article References: Novel cancer immunotherapy drug generates promising clinical trial results. Original publication (Bibliographic details unavailable.)
Image Credits: AI Generated
DOI: Not provided
Keywords: invikafusp, invikafusp alfa, cancer immunotherapy, START-001 trial, advanced solid tumors, T-cell receptor, interleukin-2 receptor, Vbeta6/Vbeta10 T cells, disease control rate, Mass General Brigham Cancer Institute, Marengo Therapeutics, National Cancer Institute, Memorial Sloan Kettering Cancer Center, Princess Margaret Cancer Centre, ESMO Congress 2026, Nature Medicine
News Source: Nathaniel Bowman. (November 11, 2026). Invikafusp Achieves 59.3% Disease Control in Advanced Solid Tumor Trial. Scienmag.



